Bio-Techne Corporation

NMS: TECH
Live Quote

📈 ZcoreAI Score

Our AI model analyzes Bio-Techne Corporation's price action across multiple timeframes using regression channels and statistical scoring.

Get TECH Z-Score →

About Bio-Techne Corporation

Healthcare Biotechnology
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

📊 Fundamental Analysis

Bio-Techne Corporation demonstrates a profit margin of 6.7%, which is below the sector average, suggesting competitive pressure.

The company recently reported -0.4% revenue growth, which is negative, indicating a recent decline in revenue.

Return on Equity (ROE) is 4.0%, which suggests room for improvement in capital utilization.

At a current price of $55.54, TECH currently sits at the 36th percentile of its 52-week range (Range: $46.01 - $72.16).

💰 Valuation Insight

TECH trades at a 319.2% premium to the sector average PE of 25.00. Analysts expect earnings growth, as indicated by a lower forward PE.

🏥 Financial Health

🔴 Profit Margin Weak
Debt/Equity Excellent
🔴 Revenue Growth Weak
🔴 Return on Equity Weak
🔴 Beta (Risk) High Volatility

Key Financials

Market Cap
$8.69B
Trailing P/E
104.79
Forward P/E
25.67
Beta (5Y)
1.49
52W High
$72.16
52W Low
$46.01
Avg Volume
2.43M
Day High
Day Low
Get TECH Z-Score on Dashboard 🚀